Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Donna ReeceJoris DielsSuzy Van SandenLixia PeiEric AmmannChristoph HeuckColleen KaneAnil LondheSteve PetersonAjai Chari

Published in: Current medical research and opinion (2024)

These analyses show superior effectiveness of both talquetamab dosing schedules vs sel-dex and vs belamaf for most outcomes and highlight talquetamab as an effective treatment option for patients with TCE RRMM.

Keyphrases

multiple myeloma
randomized controlled trial
acute lymphoblastic leukemia
systematic review
acute myeloid leukemia
low dose
diffuse large b cell lymphoma
high dose
hodgkin lymphoma
adipose tissue
glycemic control
weight loss